1[1]UK prospective diabetes study (UKPDS). Tight blood pressure control and risk of macrovascular and microvascular complication in type 2 diabetes (UKPDS 38) [J]. BMJ, 1998, 317:703-13.
2[2]Scheen AJ, Lefebvere PJ. Oral anti-diabetic agents: a guide to selection[J]. Drugs, 1998, 55(2) :225-236.
4[4]Overall F, Bell D. Triple oral antidiabetic therapy in type 2 diabetes mellitus[J]. Endocrine Practice, 1998, 4(3): 146-147.
5[5]Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type 2 diabetes: results of a double-blind, placebo-controlloed, dose-response trial [J]. The American Journal of Medicine, 1997, 103:491-497.
6[6]Glaser V. New criteria for diagnosis, screening and classification [J]. Patient Care, 1998, 2(2): 12-32.
3[1]UKPDS Group.A 6-year randomized prospective controlled trial comparing sulfonylurea,insulin and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy[J].Ann intem Med,1998,128(3):165-175.
4Spiegelman BM.PPAR-gamma:adipogenic regulator and thiazolidinedione receptor.Diabetes,1998,47:507-514.
